Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia.
Claire RoddieJuliana DiasMaeve A O'ReillyMahnaz AbbasianAmaia Cadinanos-GaraiKetki VisputeLeticia Bosshard-CarterMarina MitsikakouVedika MehraHarriet RoddyJohn A HartleyVictoria SpanswickHelen L LoweBilyana PopovaLaura Clifton-HadleyGraham Mark WheelerJoanna OlejnikAdrian J C BloorDavid IrvineLeigh WoodMaria A V MarzoliniSabine DomningFarzin FarzanehMark W LowdellDavid C LinchMartin A PuleKarl S PeggsPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
AUTO1 demonstrates a tolerable safety profile, high remission rates, and excellent persistence in r/r adult B-ALL. Preliminary data support further development of AUTO1 as a stand-alone treatment for r/r adult B-ALL.
Keyphrases
- acute lymphoblastic leukemia
- allogeneic hematopoietic stem cell transplantation
- diffuse large b cell lymphoma
- electronic health record
- childhood cancer
- multiple myeloma
- hodgkin lymphoma
- big data
- stem cells
- disease activity
- rheumatoid arthritis
- combination therapy
- machine learning
- young adults
- replacement therapy
- bone marrow
- deep learning